Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ABCL

AbCellera Biologics Inc

Apr 29 • 04:00PM ET

3.84

Dollar change +0.08
Percentage change 2.13	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IBB IDNA LRNZ ONEQ AVUS AVSC SMLF BIB BBC BBP

Index	-	P/E	-	EPS (ttm)	-0.51	Insider Own	29.92%	Shs Outstand	290.82M	Perf Week	-4.24%
Market Cap	1.12B	Forward P/E	-	EPS next Y	-0.47	Insider Trans	0.00%	Shs Float	205.17M	Perf Month	-15.23%
Income	-146.40M	PEG	-	EPS next Q	-0.13	Inst Own	38.39%	Short Float	11.25%	Perf Quarter	-31.31%
Sales	38.03M	P/S	29.56	EPS this Y	4.48%	Inst Trans	11.15%	Short Ratio	16.90	Perf Half Y	-7.25%
Book/sh	3.96	P/B	0.97	EPS next Y	2.64%	ROA	-9.67%	Short Interest	23.09M	Perf Year	-42.17%
Cash/sh	2.69	P/C	1.43	EPS next 5Y	10.00%	ROE	-12.27%	52W Range	3.62 - 8.05	Perf YTD	-32.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-11.97%	52W High	-52.30%	Beta	0.40
Dividend TTM	-	Quick Ratio	7.32	Sales past 5Y	387.52%	Gross Margin	-	52W Low	6.08%	ATR (14)	0.22
Dividend Ex-Date	-	Current Ratio	7.33	EPS Y/Y TTM	-190.57%	Oper. Margin	-623.80%	RSI (14)	37.59	Volatility	6.43% 5.08%
Employees	586	Debt/Eq	0.07	Sales Y/Y TTM	-92.17%	Profit Margin	-384.99%	Recom	1.00	Target Price	14.75
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	-56.05%	Payout	-	Rel Volume	1.04	Prev Close	3.76
Sales Surprise	3.45%	EPS Surprise	-39.25%	Sales Q/Q	-57.40%	Earnings	May 07 AMC	Avg Volume	1.37M	Price	3.84
SMA20	-8.00%	SMA50	-16.09%	SMA200	-24.92%	Trades		Volume	1,426,294	Change	2.13%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy	$9
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight	$6
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight	$20
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy	$30
Nov-16-22	Initiated	Truist	Buy	$29
Dec-21-21	Initiated	The Benchmark Company	Buy	$27
Nov-19-21	Initiated	Piper Sandler	Overweight	$33
Jan-05-21	Initiated	SVB Leerink	Outperform	$45
Jan-05-21	Initiated	Stifel	Buy	$59
Jan-05-21	Initiated	Credit Suisse	Outperform	$52
Jan-05-21	Initiated	BMO Capital Markets	Outperform	$48
Jan-05-21	Initiated	Berenberg	Buy	$53

Show Previous Ratings

Apr-08-24 12:05PM	AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024 (Business Wire)
Apr-03-24 04:05PM	AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Mar-27-24 04:30PM	The 7 Best Penny Stocks to Buy in Q2 2024 (InvestorPlace)
Mar-26-24 05:25PM	Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks (Insider Monkey) -6.33%
Mar-19-24 04:05PM	AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024 (Business Wire)
09:00AM	Loading…
Mar-11-24 09:00AM	AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions (Business Wire)
Mar-05-24 04:30PM	AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 (Business Wire)
Feb-26-24 06:55AM	3 Highly Rated Biotech Stocks to Buy for 300% Gains (InvestorPlace)
Feb-23-24 04:30PM	AbCellera Announces Resignation of Board Member (Business Wire)
Feb-22-24 08:15PM	AbCellera to Present at Upcoming Investor Conferences in March (Business Wire)
Feb-21-24 09:22AM	AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.42%
07:09AM	Q4 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 11:00PM	AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript (Motley Fool)
07:00PM	AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:57PM	AbCellera Biologics Inc (ABCL) Faces Net Loss in FY 2023 Amid Strategic Shifts (GuruFocus.com)
04:05PM	Loading…
04:05PM	AbCellera Reports Full Year 2023 Business Results (Business Wire)
Jan-30-24 01:02PM	Baillie Gifford Adjusts Stake in AbCellera Biologics Inc (GuruFocus.com) -5.55%
Jan-23-24 04:05PM	AbCellera to Report Full Year 2023 Financial Results on February 20, 2024 (Business Wire)
Jan-15-24 09:30AM	3 Growth Stocks That Could Go Parabolic in 2024 (Motley Fool)
Jan-03-24 09:40AM	Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-20-23 04:05PM	AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 (Business Wire)
Dec-16-23 01:00PM	AI Meets Biotech: 3 Top Stocks Transforming Medical Science (InvestorPlace)
Dec-11-23 03:30PM	16 Best Penny Stocks To Buy For 2024 (Insider Monkey)
Nov-16-23 04:05PM	AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023 (Business Wire)
Nov-03-23 12:05PM	AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023 (Business Wire) +6.09%
10:51AM	AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:42AM	Q3 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
05:55AM	Prelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline Progress (GuruFocus.com)
05:30AM	AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-02-23 05:56PM	AbCellera Biologics Inc (ABCL) Reports Q3 2023 Earnings: Revenue Drops to $7 Million (GuruFocus.com) +7.52%
04:05PM	Loading…
04:05PM	AbCellera Reports Q3 2023 Business Results (Business Wire)
Nov-01-23 04:05PM	Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology (GlobeNewswire)
Oct-31-23 04:05PM	AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023 (Business Wire)
Oct-26-23 10:02AM	Earnings Preview: AbCellera Biologics Inc. (ABCL) Q3 Earnings Expected to Decline (Zacks)
Oct-11-23 04:05PM	AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023 (Business Wire)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-27-23 09:00AM	AbCellera Announces Two T-Cell Engager Presentations at SITC 2023 (Business Wire)
Sep-20-23 05:02PM	AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron (Business Wire)
Sep-14-23 07:03PM	Insider Buying: Veronique Lecault Acquires 20,000 Shares of AbCellera Biologics Inc (GuruFocus.com)
Sep-13-23 09:00AM	AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology (Business Wire)
Aug-31-23 10:12PM	11 Cheap Small-Cap Stocks to Buy Before the Next Breakout (Insider Monkey) -6.03%
07:37AM	10 Stocks That Could 10X Over the Next 10 Years (Insider Monkey)
Aug-19-23 10:44AM	Billionaire Stan Druckenmillers Small-Cap Stock Picks (Insider Monkey)
Aug-04-23 10:23AM	Q2 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -13.34%
01:00AM	AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript (Motley Fool)
Aug-03-23 05:35PM	AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q2 2023 Business Results (Business Wire)
Jul-26-23 01:17PM	10 Best Canadian Stocks Under $10 (Insider Monkey)
Jul-25-23 09:55AM	Does AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Expect? (Zacks)
Jul-24-23 04:05PM	AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights Request for Rehearing (Business Wire)
Jul-08-23 08:43PM	Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom (InvestorPlace)
Jul-06-23 04:05PM	AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023 (Business Wire)
Jun-17-23 09:52AM	AbCellera Biologics Insiders Added US$4.2m Of Stock To Their Holdings \ (Simply Wall St.)
May-30-23 06:50AM	Daily Vickers Top Buyers & Sellers for 05/30/2023 (Argus Research)
May-29-23 04:05PM	AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023 (Business Wire)
May-27-23 08:43AM	Strong week for AbCellera Biologics (NASDAQ:ABCL) shareholders doesn't alleviate pain of one-year loss (Simply Wall St.)
May-24-23 02:32PM	UPDATE 1-AbCellera to make C$701 million co-investment in Canada (Reuters)
01:56PM	AbCellera to make C$701 million co-investment in Canada (Reuters)
01:30PM	These Small-Cap Biotech Stocks Have the Wind at Their Back (TheStreet.com)
01:10PM	AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients (Business Wire)
May-14-23 02:57PM	7 Growth Stocks That Could Double Your Money in 2023 (InvestorPlace)
May-06-23 08:03AM	AbCellera Biologics First Quarter 2023 Earnings: EPS Misses Expectations (Simply Wall St.)
May-05-23 10:13AM	Q1 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -9.38%
12:30AM	AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript (Motley Fool)
May-04-23 05:15PM	AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-27-23 10:02AM	AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-24-23 07:46PM	7 Stocks Under $10 That Analysts Love (InvestorPlace)
Apr-17-23 09:10AM	AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023 (Business Wire)
Apr-13-23 05:50AM	1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy (Motley Fool)
Apr-11-23 07:31PM	7 Best Stocks Under $10 to Buy in April (InvestorPlace)
04:05PM	AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023 (Business Wire)
Apr-06-23 04:05PM	AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023 (Business Wire)
Apr-05-23 01:40PM	7 Thrilling Biotech Stocks for Aggressive Investors to Buy (InvestorPlace)
Mar-22-23 03:26PM	7 Stocks to Bet On if You Want to Be Richer Than Elon Musk (InvestorPlace)
09:00AM	AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease (Business Wire)
Mar-14-23 04:30PM	AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023 (Business Wire)
Mar-12-23 08:09AM	Institutional investors may adopt severe steps after AbCellera Biologics Inc.'s (NASDAQ:ABCL) latest 9.9% drop adds to a year losses (Simply Wall St.)
Feb-23-23 04:05PM	AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023 (Business Wire)
Feb-21-23 10:30PM	AbCellera Biologics (ABCL) Q4 2022 Earnings Call Transcript (Motley Fool) -7.30%
05:45PM	AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Full Year 2022 Business Results (Business Wire)
Feb-02-23 02:19PM	The 7 Most Undervalued Biotech Stocks to Buy in February 2023 (InvestorPlace)
Feb-01-23 04:05PM	AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023 (Business Wire)
Jan-24-23 04:05PM	AbCellera to Report Full Year 2022 Financial Results on February 21, 2023 (Business Wire)
08:48AM	Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock? (Zacks)
Jan-23-23 11:00AM	AbCellera Biologics Clears Key Benchmark, Hitting 80-Plus RS Rating (Investor's Business Daily)
Jan-19-23 07:00PM	AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent (Business Wire)
11:59AM	Does AbCellera Biologics (NASDAQ:ABCL) Deserve A Spot On Your Watchlist? (Simply Wall St.)
Jan-12-23 04:55AM	Strength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength? (Zacks) +6.25%
Jan-05-23 09:09AM	AbCellera Biologics Inc.'s (NASDAQ:ABCL) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? (Simply Wall St.)
Jan-04-23 04:05PM	AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 (Business Wire)
Dec-22-22 05:08AM	Trade Alert: The CEO, President & Chairperson Of AbCellera Biologics Inc. (NASDAQ:ABCL), Carl Hansen, Has Just Spent US$859k Buying A Few More Shares (Simply Wall St.)
Dec-21-22 06:46AM	Daily Vickers Top Buyers & Sellers for 12/21/2022 (Argus Research)
Dec-16-22 10:02AM	AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie (Zacks)
Dec-15-22 07:00AM	AbCellera and AbbVie Partner to Advance New Antibody Therapies (Business Wire)
Dec-14-22 08:18AM	Is There An Opportunity With AbCellera Biologics Inc.'s (NASDAQ:ABCL) 43% Undervaluation? (Simply Wall St.)
Dec-12-22 08:54AM	Implied Volatility Surging for AbCellera Biologics (ABCL) Stock Options (Zacks)
Dec-01-22 07:00AM	AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases (Business Wire)
Nov-29-22 04:10PM	IBD Stock Of The Day AbCellera Is Pulling Back Why Investors Should Be Paying Attention (Investor's Business Daily)
Nov-10-22 08:05AM	AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022 (Business Wire) +9.31%

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Veronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hansen Carl L. G.	Chief Executive Officer	May 26 '23	Option Exercise	2.70	56,125	151,538	561,250	May 30 01:14 PM
Thermopylae Holdings Ltd.	10% Owner	May 26 '23	Buy	6.52	153,000	997,728	56,012,493	May 26 02:50 PM
Booth Andrew	Chief Financial Officer	May 26 '23	Buy	6.85	14,500	99,325	153,000	May 26 02:53 PM
Lecault Veronique	Chief Operating Officer	May 05 '23	Option Exercise	0.19	250,000	47,500	2,020,122	May 09 03:02 PM

Open in Screener

ETNB

89bio Inc

Apr 29 • 04:00PM ET

8.53

Dollar change +0.27
Percentage change 3.27	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO IBB VTWO SCHA LABU VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-2.01	Insider Own	7.00%	Shs Outstand	93.27M	Perf Week	-8.38%
Market Cap	812.23M	Forward P/E	-	EPS next Y	-2.58	Insider Trans	22.92%	Shs Float	88.56M	Perf Month	-26.72%
Income	-142.19M	PEG	-	EPS next Q	-0.46	Inst Own	101.93%	Short Float	12.66%	Perf Quarter	-20.35%
Sales	0.00M	P/S	-	EPS this Y	-2.97%	Inst Trans	8.68%	Short Ratio	8.90	Perf Half Y	24.16%
Book/sh	5.75	P/B	1.48	EPS next Y	-25.16%	ROA	-35.86%	Short Interest	11.21M	Perf Year	-44.39%
Cash/sh	6.08	P/C	1.40	EPS next 5Y	11.00%	ROE	-41.33%	52W Range	6.57 - 22.93	Perf YTD	-23.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.24%	ROI	-25.26%	52W High	-62.80%	Beta	1.01
Dividend TTM	-	Quick Ratio	20.04	Sales past 5Y	0.00%	Gross Margin	-	52W Low	29.73%	ATR (14)	0.57
Dividend Ex-Date	-	Current Ratio	20.04	EPS Y/Y TTM	43.10%	Oper. Margin	0.00%	RSI (14)	32.96	Volatility	5.23% 5.16%
Employees	70	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.40	Target Price	31.89
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-2.97%	Payout	-	Rel Volume	0.46	Prev Close	8.26
Sales Surprise	-	EPS Surprise	-2.82%	Sales Q/Q	-	Earnings	Feb 29 AMC	Avg Volume	1.26M	Price	8.53
SMA20	-12.55%	SMA50	-22.23%	SMA200	-28.19%	Trades		Volume	590,480	Change	3.27%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Resumed	BofA Securities	Buy	$30
Jan-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$24 → $15
Oct-10-23	Downgrade	Oppenheimer	Outperform → Perform
Aug-28-23	Initiated	UBS	Buy	$36
Jun-13-23	Initiated	Evercore ISI	Outperform	$49
May-12-22	Upgrade	Raymond James	Outperform → Strong Buy	$33 → $12
Dec-20-21	Initiated	H.C. Wainwright	Buy	$46
Oct-26-21	Resumed	Cantor Fitzgerald	Overweight	$49
Jul-29-21	Resumed	BTIG Research	Buy	$60
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform	$65 → $35
Apr-21-21	Initiated	Cantor Fitzgerald	Overweight	$58
Oct-19-20	Initiated	Raymond James	Strong Buy	$65
Sep-25-20	Upgrade	BofA Securities	Neutral → Buy	$37 → $43
Jul-31-20	Initiated	Piper Sandler	Overweight	$54
Jul-23-20	Initiated	BTIG Research	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$58
Dec-09-19	Initiated	SVB Leerink	Outperform
Dec-09-19	Initiated	RBC Capital Mkts	Outperform
Dec-09-19	Initiated	Oppenheimer	Outperform
Dec-09-19	Initiated	BofA/Merrill	Neutral

Show Previous Ratings

Apr-17-24 04:05PM	89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors (GlobeNewswire)
Apr-05-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-03-24 07:01PM	89bio Inc CEO Rohan Palekar Sells 52,718 Shares (GuruFocus.com)
Mar-27-24 08:00AM	89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis (GlobeNewswire)
Mar-18-24 07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal) -6.80%
07:07AM	Loading…
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 08:00AM	89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis (GlobeNewswire)
Mar-08-24 04:05PM	89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-07-24 01:34PM	Hedge Fund and Insider Trading News: Ray Dalio, Bill Ackman, Crispin Odey, Glen Kacher, Julian Robertson, Nelson Peltz, Brevan Howard Asset Management, SLR Investment Corp. (SLRC), 89bio, Inc. (ETNB), and More (Insider Monkey) +7.34%
Mar-05-24 04:05PM	89bio to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire) -14.81%
09:55AM	Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade (Zacks)
09:30AM	89BIO (ETNB) Just Overtook the 200-Day Moving Average (Zacks)
Mar-04-24 04:04PM	Why Akero Rocketed And Pulled Rival 89bio Higher On Results In Liver Disease Treatment (Investor's Business Daily) +9.11%
12:30PM	Data Suggests Makers of Fatty Liver Treatments Wont Be Displaced by Obesity Drugs (The Wall Street Journal)
09:23AM	Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment (Investor's Business Daily)
04:31AM	Loading…
Mar-02-24 04:31AM	89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ... (GuruFocus.com)
Feb-29-24 04:05PM	89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Feb-22-24 03:55AM	11 Best Small-Cap Growth Stocks to Invest In (Insider Monkey)
Feb-06-24 04:05PM	89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -17.04%
Feb-05-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-18-24 09:35AM	89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Jan-10-24 09:55AM	Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect? (Zacks)
Dec-19-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-12-23 07:30AM	89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-07-23 07:00AM	89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-06-23 04:36PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-04-23 07:00AM	89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024 (GlobeNewswire) +7.74%
Nov-27-23 08:00AM	89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) (GlobeNewswire)
Nov-21-23 04:01PM	89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference (GlobeNewswire)
Nov-12-23 12:15PM	89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting 2023 (GlobeNewswire)
07:28AM	Loading…
Nov-09-23 07:28AM	89bio Inc (ETNB) Reports Increased R&D and G&A Expenses in Q3 2023 (GuruFocus.com)
Nov-08-23 04:01PM	89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.27%
Oct-17-23 08:00AM	89bio to Participate in the H.C. Wainwright 7 Annual NASH Investor Conference (GlobeNewswire)
Oct-11-23 03:49AM	Texas Instruments margins in for a squeeze; Silk Road walloped: 5 big analyst cuts (Investing.com) -13.04%
Oct-10-23 04:13PM	Why Shares of 89bio Plummeted on Tuesday (Motley Fool) -37.06%
Oct-03-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-21-23 08:00AM	89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH) (GlobeNewswire)
Sep-20-23 08:00AM	89bio to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -9.84%
Sep-05-23 08:00AM	89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 04:01PM	89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-12-23 04:30PM	89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-07-23 09:40AM	Are Medical Stocks Lagging 89BIO (ETNB) This Year? (Zacks)
08:00AM	Obesity Drugs Wont Starve These Other Potential Blockbusters (The Wall Street Journal)
Jun-24-23 05:05AM	89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine (GlobeNewswire)
05:01AM	Data from 89bios ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress (GlobeNewswire)
Jun-07-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023 (GlobeNewswire)
May-29-23 09:35AM	89BIO (ETNB) Just Overtook the 20-Day Moving Average (Zacks)
May-23-23 08:00AM	89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) (GlobeNewswire)
May-13-23 08:53AM	Institutional investors are 89bio, Inc.'s (NASDAQ:ETNB) biggest bettors and were rewarded after last week's US$90m market cap gain (Simply Wall St.)
May-05-23 09:55AM	Wall Street Analysts Predict a 57.05% Upside in 89BIO (ETNB): Here's What You Should Know (Zacks)
May-04-23 04:05PM	89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-23 08:00AM	89bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-29-23 08:25AM	3 Biotech Buyout Targets to Watch (Motley Fool)
Apr-13-23 09:55AM	Wall Street Analysts See a 79.36% Upside in 89BIO (ETNB): Can the Stock Really Move This High? (Zacks) +6.78%
09:40AM	Is 89BIO (ETNB) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-02-23 08:27AM	Independent Director Michael Hayden Just Bought 41% More Shares In 89bio, Inc. (NASDAQ:ETNB) (Simply Wall St.)
Mar-24-23 10:57AM	Why Shares of 89bio Soared This Week (Motley Fool)
07:00AM	89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock (GlobeNewswire)
Mar-22-23 04:16PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +25.16%
04:09PM	Top 1% Biotech 89bio Scores 25% Gain As Battle In Liver Disease Heats Up (Investor's Business Daily)
09:14AM	89bio Rockets 30% And Akero Dives On A Scorching Battle In Liver Disease (Investor's Business Daily)
07:00AM	89bios Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks (GlobeNewswire)
Mar-21-23 05:10PM	12 Best Biotech Stocks To Buy Under $20 (Insider Monkey) -7.06%
Mar-15-23 09:55AM	Wall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High? (Zacks) -9.29%
Mar-10-23 08:00AM	89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -5.96%
Mar-04-23 01:30PM	89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (GlobeNewswire)
Feb-21-23 08:00AM	89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (GlobeNewswire)
Feb-08-23 08:00AM	89bio to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-24-23 09:28AM	Blueprint Medicines' (BPMC) Aykavit sNDA Gets FDA Priority Tag (Zacks)
Jan-22-23 09:21AM	With stock up 19%, Insiders of 89bio, Inc. (NASDAQ:ETNB) must be wishing they had bought more last year (Simply Wall St.)
Jan-04-23 04:01PM	89bio Provides Business Update and Outlook for 2023 (GlobeNewswire)
Dec-12-22 06:30PM	89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology (GlobeNewswire)
Nov-25-22 04:04AM	Analysts Say These 2 Strong Buy Stocks Are Their Top Picks for 2023 (TipRanks)
Nov-10-22 04:05PM	89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-05-22 01:00PM	89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022 (GlobeNewswire)
Oct-13-22 08:00AM	89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference (GlobeNewswire)
Sep-26-22 09:21AM	10 Best Biotech Stocks Under $10 (Insider Monkey) +5.66%
Sep-07-22 08:00AM	89bio to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +5.79%
Sep-01-22 10:17AM	10 Best Biotech Stocks Under $10 (Insider Monkey)
Aug-26-22 08:05AM	89bio's Pegozafermin Data Shows Improved Liver Fat, Glycemic Control (Benzinga)
06:00AM	89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022 (GlobeNewswire)
Aug-18-22 08:00AM	89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASH (GlobeNewswire) +9.49%
Aug-15-22 08:23AM	Insiders at 89bio, Inc. (NASDAQ:ETNB) recouped some losses this week after buying this year, still down US$20k (Simply Wall St.) +8.97%
Aug-11-22 08:00AM	89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-11-22 02:15PM	This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations (Benzinga) -7.56%
Jul-05-22 08:05AM	What Kind Of Shareholders Hold The Majority In 89bio, Inc.'s (NASDAQ:ETNB) Shares? (Simply Wall St.) -6.79%
08:00AM	89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants (GlobeNewswire)
Jun-29-22 01:47AM	89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants (GlobeNewswire)
Jun-28-22 04:02PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and Warrants (GlobeNewswire)
04:01PM	89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) (GlobeNewswire)
Jun-21-22 08:00AM	89bio to Present Additional Pegozafermin Data at EASL International Liver Congress 2022 (GlobeNewswire)
Jun-02-22 10:57AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $30 (Or More) (TipRanks) +15.17%
May-11-22 04:05PM	89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -7.73%
May-03-22 08:00AM	89bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-26-22 08:00AM	89bio to Host Key Opinion Leader Webinar on Severe Hypertriglyceridemia (SHTG) (GlobeNewswire)
Mar-25-22 08:35AM	89bio's stock gains 12% as Wall Street gets excited about the company's experimental NASH drug (MarketWatch)
Mar-24-22 04:05PM	89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-01-22 04:03PM	Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update (GlobeNewswire)
Feb-24-22 08:00AM	89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors (GlobeNewswire)

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PALEKAR ROHAN	Chief Executive Officer	Apr 01 '24	Option Exercise	1.93	25,000	48,250	511,889	Apr 03 04:01 PM
PALEKAR ROHAN	Chief Executive Officer	Apr 01 '24	Sale	10.91	52,718	575,153	459,171	Apr 03 04:01 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 04 '24	Buy	15.35	1,350,000	20,722,500	12,431,584	Mar 06 05:40 PM
PALEKAR ROHAN	Chief Executive Officer	Feb 26 '24	Sale	10.76	4,477	48,173	486,889	Feb 28 06:43 PM
PALEKAR ROHAN	Chief Executive Officer	Dec 29 '23	Option Exercise	1.93	50,000	96,500	351,225	Jan 03 04:54 PM
PALEKAR ROHAN	Chief Executive Officer	Dec 29 '23	Sale	11.20	50,000	560,000	301,225	Jan 03 04:54 PM
LAPORTE KATHLEEN	Director	Jul 17 '23	Option Exercise	2.64	12,500	33,000	12,500	Jul 18 06:04 PM
LAPORTE KATHLEEN	Director	Jul 17 '23	Sale	18.80	12,500	235,000	0	Jul 18 06:04 PM
PALEKAR ROHAN	Chief Executive Officer	Jun 05 '23	Option Exercise	1.93	15,000	28,950	301,978	Jun 07 05:04 PM
PALEKAR ROHAN	Chief Executive Officer	Jun 05 '23	Sale	20.00	15,000	300,000	286,978	Jun 07 05:04 PM
Atkinson Edward Morrow III	Director	Jun 01 '23	Option Exercise	2.61	6,250	16,312	6,250	Jun 05 05:03 PM
Atkinson Edward Morrow III	Director	Jun 01 '23	Sale	17.91	6,250	111,938	0	Jun 05 05:03 PM
Le-Nguyen Quoc	See Remarks	May 09 '23	Option Exercise	3.11	79,571	247,466	178,654	May 11 05:01 PM
Le-Nguyen Quoc	See Remarks	May 09 '23	Sale	18.11	13,683	247,799	164,971	May 11 05:01 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ABCL

AbCellera Biologics Inc

ETNB

89bio Inc

Upgrade your FINVIZ experience